AstraZenecaAZN
AZN
About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Employees: 94,300
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
191% more call options, than puts
Call options by funds: $855M | Put options by funds: $294M
62% more funds holding in top 10
Funds holding in top 10: 13 [Q4 2024] → 21 (+8) [Q1 2025]
58% more first-time investments, than exits
New positions opened: 147 | Existing positions closed: 93
40% more repeat investments, than reductions
Existing positions increased: 517 | Existing positions reduced: 369
10% more capital invested
Capital invested by funds: $34.1B [Q4 2024] → $37.6B (+$3.47B) [Q1 2025]
2% more funds holding
Funds holding: 1,202 [Q4 2024] → 1,224 (+22) [Q1 2025]
0.55% less ownership
Funds ownership: 33.12% [Q4 2024] → 32.57% (-0.55%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for AZN.
Financial journalist opinion
Based on 40 articles about AZN published over the past 30 days
Neutral
Proactive Investors
19 hours ago
AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts at Shore Capital said. Blue-chip shares across London and Europe were lower on Friday, after Donald Trump scaled up his tariff rhetoric again.
Negative
Proactive Investors
1 day ago
Trumps 200% tariffs. Here's what it means for UK pharma investors
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.
Positive
Proactive Investors
2 days ago
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN) should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipeline readouts that haven't yet made their way into the share price.
Positive
Zacks Investment Research
3 days ago
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales.
Positive
Seeking Alpha
3 days ago
AstraZeneca: Just What The Doctor Ordered
AstraZeneca is a classic GARP stock with robust growth, an undervalued share price, and a strong drug pipeline supporting future earnings expansion. Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations, and key therapy areas like oncology and respiratory are driving double-digit growth. Shares are trading at a 16% discount to fair value, offering 21% upside potential over the next year, with a secure, market-beating 2.3% dividend yield.
Positive
Zacks Investment Research
1 week ago
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
Positive
Seeking Alpha
1 week ago
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus Keytruda in NSCLC, but mixed OS results could delay U.S. approval and complicate regulatory pathways. Summit is doubling down on ivonescimab, expanding clinical collaborations and targeting a $90B addressable market beyond NSCLC.
Positive
Proactive Investors
1 week ago
AstraZeneca wins EU approval for Imfinzi in early bladder cancer treatment
AstraZeneca PLC's (LSE:AZN) cancer drug Imfinzi has been approved in the European Union for use before and after surgery in patients with muscle-invasive bladder cancer, marking a significant step forward in treatment options for the disease. The approval means Imfinzi is now the first and only immunotherapy authorised in Europe for use both before and after surgery, what doctors call “perioperative” treatment, in patients whose cancer has spread into the bladder muscle but is still operable.
Positive
The Motley Fool
1 week ago
Why AstraZeneca Stock Got Thumped on Thursday
AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.
Positive
CNBC Television
1 week ago
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Charts implemented using Lightweight Charts™